Skip to content


  • Oral presentation
  • Open Access

O135. A pilot study to determine the prevalence of HIV in persons presenting for care with selected conditions: preliminary results from the HIV in Europe study

  • 1,
  • 2,
  • 3,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 8,
  • 9,
  • 10,
  • 11,
  • 12,
  • 13 and
  • 13
Journal of the International AIDS Society201013 (Suppl 4) :O16

  • Published:


  • Dermatitis
  • Candidiasis
  • Herpes Zoster
  • Malignant Lymphoma
  • Sexually Transmitted Disease

Purpose of the study

A pilot study was initiated in Autumn 2009 to better define which diseases have a HIV prevalence of >0.1 % as HIV testing of populations with a HIV prevalence above this has shown to be cost-effective. The preliminary results are reported here.


A detailed questionnaire was completed for persons presenting with 8 different indicator diseases; sexually transmitted disease (STD), malignant lymphoma (LYM), cervical or anal cancer/dysplasia (CAN), herpes zoster (HER), ongoing mononucleosis-like illness (MON), unexplained leukocytopenia / thrombocytopenia lasting >4 weeks (CYT), and seborrheic dermatitis/exanthema (SEB).


1482 persons have so far been included in the pilot phase by June 2010 from 29 surveys taking place in Austria, Belarus, Belgium, Bosnia, Croatia, Denmark, Germany, Italy, Poland, Spain, Sweden and Ukraine. Selected characteristics of the patients are shown in Figure 1. Almost 40% reported a previous HIV test; this was highest in the STD (59.0%), HEP (47.5%) and SEB (44.2%) groups. Median age was highest in the LYM group (53 years), and youngest in the MON group (24 years). 104 persons (7.7%) reported one of 5 specific HIV-related symptoms in the previous 5 years (mononucleosis, oral candidiasis, herpes zoster, unexplained leukocytopenia/thrombocytopenia or seborrheic dermatitis); these symptoms were highest in the HER (33.3%), SEB (31.1%) and LYM (21.2%) groups. 134 had visited an STD clinic in the previous 5 years including over half of the STD group (56.3%). 152 had been hospitalised in the previous 5 years; the highest proportion was seen in the HEP group (70.3%). Many of the planned surveys have shown difficult to implement because of reluctance towards introducing routine HIV testing among specialists who are not used to/worried about performing an HIV test. A number of persons have tested HIV-positive.

Figure 1


The first results of this pilot study demonstrates the potential benefit of guided HIV testing of patients with selected indicator diseases, as a number of persons have been identified to be HIV-positive. A significant proportion of the persons had previously been hospitalised or reported HIV-associated symptoms but had not been tested. Physicians in some specialities are however reluctant to adopt this testing strategy.

Authors’ Affiliations

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden
Research Department of Infection and Population He, University College London Medical School, London, UK
Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark
Hospital Clinic Barcelona, Infectious Diseases Unit, Barcelona, Spain
Belarus State Medical University, Minsk, Belarus
University of Sarajevo, Infectious Diseases Clinic, Sarajevo, Bosnia and Herzegovina
University Hospital of Infectious Diseases, Zagreb, Croatia
Bispebjerg Hospital, Århus, Denmark
STD Centre, Dermatology Department, Milan, Italy
Saint-Pierre University Hospital, Brussels, Belgium
Chelsea Westminster Hospital, London, UK
University of Bonn, Bonn, Germany
San Paolo Hospital, Milan, Italy


© Sönnerborg et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.